Toxicology - Antihypertensives, Synthetic Cannabinoids, Aspirin/Salicylates, Digoxin, Sympathomimetics Flashcards

1
Q

Bradycardia with hypotension

A

*Beta blockers
*Calcium channel blockers
Digoxin
Alpha-agonist (clonidine, guanfacine, methyldopa)

Don’t have the ability to have compensatory increased HR to to maintain cardiac output

CCBs
́ Alert initially, *elevated blood sugar
́ Sustained release may delay onset

BB
́ Decreased mental status
́ Sustained release may delay onset

Digoxin
́ Need AV conduction abnormality
́ Delay in onset (GI early)

Alpha-2 agonist
́ Decreased mental status, small pupils,
́ No delay in onset

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Pathophysiology of Overdose - CCBs (DHP + non-DHP) (just read 1-2 times)

A

Verapamil + diltiazem (non-dihydropyridines)
́ Decreased ventricular contractility
́ Negative inotrope (BP)
́ Sinus node depression
́ Negative chronotrope (HR)
́ AV node depression leads to various blocks

All calcium channel blockers (including dihydropyridines)
́ Vasodilation leads to hypotension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Beta Blockers

A

Selective and non-selective
́ Membrane stabilizing activity
́ Inhibit fast sodium channels
́ CNS – depression & seizures
́ Negative inotropic effects

Pertinent Selective Beta-Blockers:
Bisoprolol
Esmolol
Atenolol
Metoprolol

Vasodilating agents:
Betaxolol Carvedilol Labetalol Nebivolol

Membrane stabilizing effects (sodium channel effect, may also widen QRS)
Acebutolol, Carvedilol, Betaxolol, Propranolol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Beta Blockers Clinical Effect

A

Toxidrome - Bradycardia, hypotension
Cardiac - AV blocks and CHF
́ Sotalol - Torsades de Pointes
́ CNS - depressed LOC
́ Propranolol - seizures (crosses BBB more than other BB)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

CCB/BB Treatment (General)

A

GI decontamination
́ Activated charcoal
́ Whole bowel irrigation

́ Fluids
́ Atropine
́ Calcium
́ Glucagon? - ONLY BETA BLOCKERS
́ High dose Insulin and glucose
́ Vasopressors
́ Inotropes
́ Cardiac Pacing
́ Intralipid
́ ECMO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Differentiation diagnostic between CCBs and BBs

A

Glucose elevation in CCB overdose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

CCB/BB Overdose Treatment

A

Fluids
́ Isotonic crystalloids
́ 0.9% normal saline, lactated ringers

Atropine
́ 0.5 - 1mg every 5 minutes for 3 doses
- if more is needed, would switch to longer acting agent

Calcium Chloride
́ 13.4 mEq/ca per 1 gram (this is 3x elemental calcium)
́ Sclerosing - more of a vesicant. Needs a larger vein or central vein to limit risk
́ Dose: 1-3g IV (adult)

Calcium Gluconate
́ 4.3mEq/ca per 1 gram
́ Veno-friendly (okay for peripheral administration)
́ Dose: 3-9g IV (adult)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

CCB/BB Overdose Treatment - Insulin and Glucose

A

Insulin and glucose (HIET – high dose insulin euglycemia therapy)
́ May shift cardiac energy from free fatty acids to carbohydrates
Dose:
́ 1 unit/kg bolus
́ 1-10 units/kg/hr
́ Glucose: administer to keep glucose > 100 mg/dL (loose target, don’t want hypo)
́ Potassium: replace as needed (goal 2.8 – 3.5) (lower end of normal because it’s just a redistribution of potassium)
́ Effects start 30-60 minutes after dosing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

CCB/BB Overdose Treatment part 2

A

Vasopressors
́ Norepinephrine, epinephrine

Inotropes
́ Dobutamine (beta agonist), milrinone (vasodilating, PDE inhibitor)

CardiacPacing

Intralipid
́ MOA: ‘lipid sink’ – pulls toxin off of a site of toxicity into intravascular space
́ MOA: modulator of myocardial energy – enhances fatty acid intracellular transport

VA-ECMO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

CCB/BB Overdose Treatment - Glucagon?

A

? Because early tachyphylaxis —> will stop working. Still is a viable option

Does what beta receptor does to increase cAMP and increase contractility

́ Benefit after beta blockers (not CCB)
Dose:
́ Initial: 3-5mg (up to 10mg) bolus
́ Infusion: 3-5mg/hour

Side effects:
́Vomiting – limited use with altered mental status
(Use with anti-emetic)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Other antihypertensives and treatment

A

́ Alpha-2 agonists
́ Alpha-1 antagonists
́ Vasodilators
́ ACEi/ARB

Supportive Care
Fluids
Atropine (if HR goes low)
Vasopressors

Won’t regularly go to insulin or other options in these overdoses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Other Antihypertensives and Treatment - Clonidine

A

́ Transient hypertension and tachycardia
́ Bradycardia and hypotension
́ CNS depression
́ Respiratory depression

Treatment:
́ Naloxone 5-10mg bolus +/- infusion - very high dose, most providers not comfortable
́ May reverse respiratory depression
́ Supportive care

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Types of Cannabinoids

A

Phytocannabinoids - plant derived (CBD, THC, CBN, etc)
THC is the main component of marijuana that is responsible for the major psychoactive effects
́ THC partial agonism at CB1 receptors (this is why smoking marijuana has HIGH therapeutic index)
́ Mood elevation, euphoria, relaxation, creative thinking, and increased sensory awareness

Endocannabinoids - Brain-derived

Synthetic Cannabinoids - Chemically Engineered

All bind to endocannabinoid receptors CB1 and CB2

Marijuana is still illegal under federal law

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Endocannabinoids receptors functions

A

CB1 Receptors
́ CNS
́ GPCRs
́ Motor Activity
́ Thinking
́ Pain perception

CB2 Receptors
́ Periphery
́ GPCRs
́ Immune modulation
́ Anti-inflammatory

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Clinical Effects of Phytocannabinoids (just read 1-2 times)

A

Wanted Effects
• Mood elevation
• Euphoria
• Relaxation
• Creative thinking
• Increased sensory awareness
• Appetite stimulation
• Nausea suppression

Paradoxical Effects
• Short-term memory difficulties
• Agitation
• Feeling tense
• Anxiety
• Dizziness
• Lightheadedness
• Confusion
• Loss of coordination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Street Names for Cannabinoids

A

“K2” or “Spice”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Synthetic Cannabinoids

A

́ AB-CHIMINACA
́ AMB-FUBINACA
́ Naming system based on chemical structure
́ N-(1-Adamantyl)-1-Pentyl-1H-INdAzole-3- Carboxamide
́ APINACA

Structure-Activity relationship. Minor changes result in big effects

Synthetic cannabinoids are much more potent than phytocannabinoids and can have unpredictable effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Differences in Cannabinoids

A

Synthetic Cannabinoids
́ Full agonists
́ Higher receptor affinity
́ Longer half-lives

Ki = affinity. Lower # = higher affinity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Clinical Presentation (idk that we’ll be asked this)

A

Signs and Symptoms
• CNS depression
• Disorientation
• Restlessness/agitation
• Hallucinations
• Seizures, generalized • Combativeness
• Anxiety
• Mydriasis
• Tachycardia
• Vomiting

Lab abnormalities
• ↓ Potassium
• ↑ Blood glucose
• ↑ Creatinine kinase
• ↑ White blood cells
• ↑ Creatinine

20
Q

Management (most common sx) - Cannabinoids

A

Agitation
• IM/IV lorazepam 2-4mg (titrate to effect)
• IM/IV Midazolam 5-10mg (titrate to effect)
• IM/IV Haloperidol 2.5 – 10mg
• IM/IV Olanzapine 5 – 10mg
• IM/IV Droperidol 2.5mg – 10mg

Seizures
• IV lorazepam 2-4mg
• IM midazolam 5-10mg
• IV diazepam 5-10mg
• Antiepileptics – unclear role (because they don’t remove drug toxin, but not a hard no)

Nausea / Vomiting

Dehydration
• IV crystalloids

Hypertension / Tachycardia
• IM/IV Benzodiazepines
• IV antihypertensives as necessary

21
Q

Cannabinoids Hyperemesis Syndrome

A

Excessive vomiting due to chronic cannabinoid use
Pathophysiology
́ Dysregulation of endocannabinoid system
́ Desensitization and downregulation of CB1 receptors that generally have antiemetic effects
́ Alteration in TRPV1 receptor (transient receptor potential vanilloid subtype 1) after chronic cannabinoid use
Diagnosis
́ History of regular cannabis use
́ Cyclic nausea and vomiting
́ Generalized, diffuse abdominal pain
́ Compulsive hot showers with symptom improvement

22
Q

Cannabinoids Hyperemesis Syndrome Phases

A

Pre-emetic or Prodromal Phase
• Months to years
• Diffuse abdominal discomfort, feelings of agitation or stress, morning nausea, and fear of vomiting
• Increased use of marijuana to treat

Hyperemetic Phase
• 24 – 48 hours
• Cyclic episodes of nausea and vomiting
• Diffuse, severe abdominal pain

Recovery Phase
• Upon total cessation of cannabis
• Bowel regimens, fluids, electrolyte replacement
• Full resolution may take ~ 1 month

23
Q

Cannabinoids Hyperemesis Syndrome Clinical Management

A

Hot showers
• Activate TRPV1
Capsaicin topical cream (apply to abdomen)
• Activate TRPV1
• Anti-nausea (HaVOC Trial: Haloperidol was superior to ondansetron for improvement of nausea and abdominal pain at 120 minutes)
• Haloperidol
• Ondansetron
• Benzodiazepines
• Inhibitory effects on medullary and vestibular nuclei associated with nausea and vomiting
• Supportive care
• Fluids, electrolytes

24
Q

Sources of Salicylate

A

́ Various analgesics (OTC)
́ GI remedies
́ Pepto-bismol (9mg/ml)
́ Alka-seltzer (325mg)
́ Topical balms
́ Icy hot
́ Bengay
́ Oil of wintergreen (1440mg/ml)

25
* TOXIC DOSE * - Aspirin / Salicylates
Acute overdose ́ **Greater than 150mg/kg** ́ **Life threatening > 500mg/kg** Chronic overdose ́ Less clearly established ́ Greater toxicity at lower doses ́ Oil of wintergreen ́ 98% methyl salicylate ́ 98g/100ml ́ 20.4ml = 20g life threatening for 70kg adult ́ 5.1ml = 5g life threatening for 10kg child ́ 1.5ml = seek medical attention for 10kg child
26
Pharmacokinetics of Aspirin / Salicylates
Absorption ́ Aspirin ́ Absorption can be delayed (pylorospasm, enteric coated, **concretions/bezoars**) ́ Other salicylates ́ Absorption varies according to the dosage form ́ Methyl salicylate will be absorbed quickly Distribution ́ Protein binding 50-90% (decreased in OD) ́ Vd = 0.1-0.2 L/kg (small), larger in acidosis Elimination ́ Hepatic and renal: normal half life 2-4 hours Overdose ́ Michaelis-Menten kinetics ́ Half life extends Significant overdose ́ Renal elimination plays a greater role
27
Mechanism of Toxicity - Aspirin/Salicylates
Metabolic acidosis ́ Salicylic acid (minor) ́ **Uncoupled oxidative phosphorylation (major)**
28
Clinical Manifestations - Aspirin / Salicylates
Respiration ́ Potent stimulatory effects on respiratory drive ́ Tachypnea/hyperpnea GI ́ Disrupts mucosal barrier ́ n/v, hemorrhagic gastritis, volume depletion CNS ́ Neuronal energy depletion, **hypoglycorrachia (neuroglycopenia)** - decreased BG in CNS, but not necessarily in the bloodstream ́ Tinnitus, altered mental status, hyperpyrexia, tachycardia, fever, coma, seizures Other ́ Non-cardiogenic pulmonary edema (chronic), renal and hepatic injury
29
Laboratory Manifestations - Aspirin/Salicylates
Acid / Base ́ EARLY: respiratory alkalosis (direct stimulation) ́ MIDDLE: mixed metabolic acidosis and respiratory alkalosis ́ LATE/PRETERMINAL: metabolic and respiratory acidosis Electrolytes ́ hypo or hyperglycemia, (CNS hypoglycemia) ́ increased fluid and electrolyte losses ́ increased anion gap (MUDPILERS. S = Salicylates) Urine ́ urine ketones will be positive
30
Chronic Overdose - Aspirin/Salicylates
́ Acute overdose may be present ́ Slower, more insidious onset ́ N/V, **tinnitus**, dyspnea, hyperthermia, neurologic manifestations ́ More common to be misdiagnosed Delirium, dementia, encephalopathy Pulmonary edema more common Increased PT/LFTs ́ Lower levels will produce toxic effects ́ Enlarged volume of distribution
31
Management - Aspirin / Salicylates
́ Airway, breathing, circulation - ABCs ́ ***maintain ventilation – do not intubate*** ́ Multiple serum salicylate levels ́ Enhance elimination ́ multiple doses of activated charcoal 1 g/kg (loss of 10:1 ratio) ́ urine alkalization (pH > 7.5) ́ hemodialysis ́ Treat adverse effects ́ seizures, cerebral edema, hypoglycemia, dysrhythmias
32
Bezoar
Concentrated lump of aspirin/Salicylates which slowly releases salicylates over time in the GI tract
33
Ion Trapping - Aspirin/Salicylates
Alkalize the urine to make H+A- cross to the urine, become ionized to attempt to neutralize it, and then the ions can’t cross back into the bloodstream Significantly higher urinary clearance with increasing Urinary Alkylinization Is a learning objective! (1 of 2 for the aspirin lecture)
34
Management of Aspirin / Salicylate Overdoses
́ **Give dextrose (even if normal glucose levels)** ́ 0.5-1g/kg ́ Fluid maintenance ́ Serum pH 7.45 – 7.55 ́ **150mEq SODIUM BICARBONATE in D5W at twice maintenance rate** ́ Urine pH > 7.5 ́ Maintain potassium ́ Monitor Mental status, urine and blood pH, salicylate levels, fluid and electrolytes q 2-4 hours
35
Hemodialysis Indications - Aspirin/Salicylates
́ Serum level ́ Acute: > 100mg/dL ́ Lower threshold in impaired kidney function ́ Chronic > 60mg/dL ́ Neurologic deterioration ́ Seizures ́ Intractable acidosis ́ pH < 7.20 ́ Renal failure ́ Pulmonary edema **Continue hemodialysis until**: -Clear improvement in patient -Salicylate level < 19mg/dL -HD completed for 4-6 hours and levels not obtainable
36
Acute Digoxin Toxicity
Gastrointestinal system - Nausea, vomiting, diarrhea Central nervous system - Headaches, confusion, delirium - Visual (halos/colors) Metabolic derangements - Hyperkalemia Predistribution - Nausea, vomiting - Hyperkalemia Post-distribution - Hypotension - Bradycardia - Dysrhythmias - Death
37
Digoxin Toxicity - Hyperkalemia
Acute, single ingestions Normal organ function **K+ > 5.5mEq/dL = all died** **K+ < 5.0mEq/dL = all survived** K+ 5.0 - 5.5mEq/dL = mixed Digoxin Cardiac ECG - **Prolonged PR interval** - Salvador Dali’s mustache
38
Digoxin Toxicity
Cardiac - Decreased conduction - Enhanced automaticity - Classic rhythms: PVC’s bidirectional ventricular tachycardia, atrial tachycardia with block **any rhythm except rapidly conducting SVT’s**
39
Treatment for Digoxin Toxicity
Gastrointestinal decontamination - Activated charcoal, repeat doses in renal failure Hyperkalemia - Digoxin specific FAB fragments ; Temporizing measures **Digoxin specific FAB fragments (Digifab)** - Derived from sheep ; Digoxin-specific antibody formed - Fc fraction (antigenic) cleaved - Increased volume of distribution - Less allergy Digifab dose: 1 vial binds 0.5mg digoxin ingested. Unknown amount? —> 10 vials Digifab In Practice… - Give 2 vials and titrate to effect - Give Q1 hour if no response seen Without digibind – **phenytoin** is the antidysrhythmic classically of choice
40
Indications for Digifab Use
Potassium > 5 mEq/L Level > 20 mcg/L Progressing signs of toxicity
41
Chronic Digoxin Toxicity
Less common to present with typical manifestation and potassium is unhelpful Digifab indications are soft and include: - Post-distribution level of > 6 mcg/L (~6 after last ingestion) - Progressing or severe signs of toxicity Unknown digoxin dose (#Digifab vials): - 5 in adults - 3 in children In practice… Give 1-2 vials and titrate to effect Give Q1 hour if no response seen
42
What is a Sympathomimetic?
Inhibition of norepinephrine and dopamine reuptake, or increased release of neurotransmitters “Uppers”
43
Types of Sympathomimetics and General Management
Cocaine, Amphetamines, Bath Salts, Pseudoephedrine, Nootropics (said to promote intelligence) NO ANTIDOTE Supportive Care • Elimination strategies (i.e. activated charcoal) • **Benzodiazepines** • Anti-hypertensives • Fluids • Anti-psychotics (if agitated or combative - haloperidol or olanzapine) • Electrolyte management • Ice baths (Temp too high—> Cool them down quickly • Sodium bicarbonate (if acidosis present) Bupropion and Pseudoephedrine have similar chemical structures
44
Cocaine
Sympathomimetic Typical Line = 20-30 mg ́ **Ingestion of 1 gram is likely to be fatal** ́ Euphoria, seizures, dysrhythmias, hypertension ́ Coronary artery spasm myocardial infarction ́ Adulterants ́ Levimasole: neutropenia, vasculitis, purpura ́ Body Packers ́ **Management: Benzodiazepines, supportive care**
45
Amphetamines
Mechanism of action: releases catecholamines ́ Clinical manifestations: adrenergic ́ Similar to cocaine though longer lasting ́ Agitation, seizures, hyperthermia, hypertension, delirium ́ Management: benzodiazepines, barbituates, anti- hypertensives ́ Supportive care
46
Bath Salts
Syntheticcathinones ́ Agitation ́ Tachycardia ́ Insomnia ́ Paranoia ́ Seizures ́ Violent, unpredictable behavior ́ Management: Supportive are
47
Supportive Care - Sympathomimetics
Clinical Effects • Benzodiazepines Airway protection • Intubation Hyperthermia • Ice packs • Cool fluids • Antipyretics (may or may not work) • Benzodiazepines Dysrhythmias • Sodium bicarbonate • Lidocaine Rhabdomyolysis • Fluids